Purchase this article with an account.
Ahmad M Mansour, Muhammad H Yunis, Marwan Al Sabban, Sara Al Ghadban; Ziv-aflibercept in macular disease. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2299.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Aflibercept is an approved therapy for neovascular macular degeneration (AMD) and diabetic macular edema (DME). In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using the approved cancer protein, ziv-aflibercept. Our purpose is to determine if ziv-aflibercept can be used in AMD and DME without ocular toxicity, to test the stability of ziv-aflibercept, and to do a cost analysis.
Prospectively, consecutive patients with AMD or DME and poor vision underwent one intravitreal injection of 0.05 ml of fresh filtered ziv-aflibercept (1.25mg). Monitoring of best-corrected visual acuity, intraocular inflammation, cataract progression, and retinal structure by spectral domain OCT was done at one day and one week after injection. Ziv-aflibercept activity over 4 weeks was measured by capturing VEGF by ELISA.
There were no signs of retinal toxicity, intraocular inflammation, or change in lens status in 4 eyes with AMD and 2 eyes with DME. Visual acuity improved (p=0.003) and central foveal thickness decreased in all patients (p=0.03). Ziv-aflibercept had no loss of anti-VEGF activity when kept at 4° C in polycarbonate syringes over 4 weeks. Similar to bevacizumab, compounded ziv-aflibercept would yield a tremendous saving compared to aflibercept or ranibizumab.
Off label use of ziv-aflibercept improves visual acuity without ocular toxicity and may offer a cheaper alternative to the same molecule aflibercept.
This PDF is available to Subscribers Only